Rhumbline Advisers Lowers Stock Holdings in Vaxcyte, Inc. $PCVX

Rhumbline Advisers lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 7.7% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 183,212 shares of the company’s stock after selling 15,275 shares during the quarter. Rhumbline Advisers owned approximately 0.14% of Vaxcyte worth $6,599,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in PCVX. Norges Bank acquired a new position in Vaxcyte in the second quarter valued at $32,109,000. Westfield Capital Management Co. LP grew its holdings in Vaxcyte by 42.4% in the 2nd quarter. Westfield Capital Management Co. LP now owns 3,068,898 shares of the company’s stock valued at $99,770,000 after buying an additional 913,761 shares during the period. Qube Research & Technologies Ltd acquired a new position in shares of Vaxcyte during the 2nd quarter valued at about $26,318,000. State Street Corp lifted its holdings in shares of Vaxcyte by 12.1% during the 2nd quarter. State Street Corp now owns 4,942,235 shares of the company’s stock worth $160,672,000 after acquiring an additional 534,552 shares during the period. Finally, Eventide Asset Management LLC lifted its holdings in shares of Vaxcyte by 80.4% during the 2nd quarter. Eventide Asset Management LLC now owns 848,141 shares of the company’s stock worth $27,573,000 after acquiring an additional 377,911 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Vaxcyte Stock Performance

NASDAQ:PCVX opened at $58.51 on Monday. The stock has a market cap of $7.66 billion, a price-to-earnings ratio of -12.09 and a beta of 1.33. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $84.01. The business’s 50-day simple moving average is $50.05 and its 200 day simple moving average is $43.01.

Insider Transactions at Vaxcyte

In other Vaxcyte news, insider Harpreet S. Dhaliwal sold 9,743 shares of the company’s stock in a transaction that occurred on Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total transaction of $454,900.67. Following the sale, the insider owned 23,928 shares in the company, valued at $1,117,198.32. This represents a 28.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, SVP Elvia Cowan sold 11,623 shares of Vaxcyte stock in a transaction that occurred on Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total value of $556,974.16. Following the completion of the transaction, the senior vice president owned 14,534 shares of the company’s stock, valued at approximately $696,469.28. The trade was a 44.44% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on PCVX shares. Needham & Company LLC boosted their target price on shares of Vaxcyte from $90.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, January 9th. BTIG Research restated a “buy” rating and set a $85.00 price objective on shares of Vaxcyte in a report on Monday, November 10th. Guggenheim restated a “buy” rating and set a $116.00 price objective on shares of Vaxcyte in a report on Monday, February 2nd. Finally, Leerink Partners set a $77.00 target price on Vaxcyte and gave the company an “outperform” rating in a report on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.83.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.